Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Acquired by Douglass Winthrop Advisors LLC

Douglass Winthrop Advisors LLC raised its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 70.1% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 364 shares of the biopharmaceutical company’s stock after purchasing an additional 150 shares during the period. Douglass Winthrop Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $259,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Thrivent Financial for Lutherans grew its holdings in Regeneron Pharmaceuticals by 16.7% in the 3rd quarter. Thrivent Financial for Lutherans now owns 9,120 shares of the biopharmaceutical company’s stock worth $9,587,000 after buying an additional 1,306 shares in the last quarter. Prospera Financial Services Inc bought a new position in shares of Regeneron Pharmaceuticals in the third quarter worth $778,000. PNC Financial Services Group Inc. increased its holdings in shares of Regeneron Pharmaceuticals by 0.8% during the third quarter. PNC Financial Services Group Inc. now owns 18,325 shares of the biopharmaceutical company’s stock valued at $19,264,000 after purchasing an additional 153 shares during the period. Integrated Investment Consultants LLC raised its stake in shares of Regeneron Pharmaceuticals by 85.1% during the third quarter. Integrated Investment Consultants LLC now owns 570 shares of the biopharmaceutical company’s stock valued at $599,000 after purchasing an additional 262 shares in the last quarter. Finally, Pacer Advisors Inc. lifted its holdings in Regeneron Pharmaceuticals by 18.7% in the third quarter. Pacer Advisors Inc. now owns 19,540 shares of the biopharmaceutical company’s stock worth $20,541,000 after purchasing an additional 3,076 shares during the period. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

NASDAQ REGN opened at $658.48 on Friday. The company has a 50 day simple moving average of $689.43 and a 200-day simple moving average of $818.17. Regeneron Pharmaceuticals, Inc. has a 52-week low of $642.00 and a 52-week high of $1,211.20. The firm has a market capitalization of $71.99 billion, a price-to-earnings ratio of 17.20, a price-to-earnings-growth ratio of 2.34 and a beta of 0.27. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The company had revenue of $3.79 billion during the quarter, compared to the consensus estimate of $3.76 billion. During the same quarter in the prior year, the firm earned $11.86 EPS. The company’s revenue was up 10.3% compared to the same quarter last year. Equities research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th were paid a $0.88 dividend. The ex-dividend date was Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.53%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 2.30%.

Analyst Ratings Changes

A number of analysts have commented on the stock. Citigroup dropped their price target on shares of Regeneron Pharmaceuticals from $795.00 to $750.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 28th. Truist Financial dropped their target price on Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating on the stock in a report on Wednesday, January 8th. Canaccord Genuity Group lowered Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, December 17th. Leerink Partnrs raised Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, February 5th. Finally, Wells Fargo & Company decreased their target price on Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating for the company in a research note on Friday, January 10th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have assigned a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Regeneron Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $973.13.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.